)
Denali Therapeutics (DNLI) investor relations material
Denali Therapeutics Jefferies Global Healthcare Conference summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.AVLAYAH launch and commercial outlook
AVLAYAH launched for Hunter syndrome; the U.S. population is ~500, with 375 eligible under the current pediatric label, and ~1,500 additional patients worldwide.
The launch has completed two successful quarters; the commercial goal is to become the market leader by treating new patients and capturing prevalent patients switching from current ERT.
U.S. annual cost for a 30-kg patient is ~$800,000, versus $500,000 for current ERT; adult label expansion and international access are important growth drivers.
The 2026 Q4 revenue guidance is $30M-$32M; revenue generation is expected to extend the operating runway.
COMPASS includes 65 patients in neurologic and somatic/peripheral cohorts; its two-year endpoint is due at end-2027, with readout expected in 2028.
Sanfilippo program
A Sanfilippo BLA filing is planned for 2027; the opportunity is considered similar to Hunter syndrome, though prevalence estimates are harder to establish.
Initial results in the first eight patients showed an average 80% reduction in CSF heparan sulfate; a subset normalized the biomarker, while higher anti-drug antibodies were seen in some patients.
The WORLD 2027 presentation is planned to include all 20 patients, including 12 treated at the intended marketed dose; the dataset will include CSF heparan sulfate and other biomarkers.
GM3 normalized in six of seven patients in an earlier dataset; the Phase III confirmatory study has begun and includes Bayley, with Vineland among key secondary endpoints.
Enrollment and study design are being considered in light of Ultragenyx’s gene therapy approval, with ongoing FDA engagement on alignment for the program.
FTD-GRN program
The progranulin replacement program targets FTD patients with granulin mutations, estimated at 6%-10% of the overall FTD population.
Treatment duration was extended from six to 12 months to improve the opportunity to assess proximal lysosomal biomarkers and distal neurofilament light chain, which can take time to change.
After reviewing the totality of study data, the team plans to discuss a potential accelerated approval pathway with the FDA; future program steps will depend on the data.
- AVLAYAH launch momentum builds as Hunter, Sanfilippo and Alzheimer’s programs advance.DNLI
UBS Global Biopharma Conference 2026 - AVLAYAH ramps as a broad pipeline advances toward key 2027 readouts.DNLI
Stifel 2026 Healthcare Conference 2026 - AVLAYAH sales accelerated as multiple pipeline programs approach 2027 readouts.DNLI
Q3 2026 - AVLAYAH's launch validates a brain-targeted biologics platform, driving pipeline and global expansion.DNLI
Morgan Stanley 24th Annual Global Healthcare Conference - AVYLAH's strong launch and a robust pipeline position the company for major growth by 2027.DNLI
12th Annual Cantor Fitzgerald Global Healthcare Conference - Transformative BBB-penetrant therapies drive growth, with AVLAYAH leading a $1B+ opportunity.DNLI
Corporate presentation - AVLAYAH's launch drove $3.6M revenue, $195M PRV sale, and Q3 guidance of $10–12M.DNLI
Q2 2026 - DNL310 targets accelerated approval in early 2025, with broad pipeline and platform expansion underway.DNLI
Morgan Stanley 22nd Annual Global Healthcare Conference - Two near-term launches and $275M funding accelerate growth in BBB-enabled rare disease therapies.DNLI
Investor Day 2025
)
)
)
)
)
)
)
)